Le Lézard
Classified in: Health, Science and technology, Business
Subject: JVN

Transplant Connect to Expand Human Biologics Management Software with Investment from InVita Healthcare Technologies


LOS ANGELES, Jan. 18, 2022 /CNW/ -- Transplant Connect, the world's leading software provider for the donation and transplantation field, is pleased to announce an investment from InVita Healthcare Technologies. InVita provides leading chain of custody software for complex medical environments including blood, plasma, tissue, implant, and forensic DNA. This strategic investment will help accelerate the continued expansion of Transplant Connect's iTransplant? clinical information, communications, analytics and logistics platform and its many innovations, such as the company's iReferral? automated donor referral technology. 

"We welcome Transplant Connect and its world-class products to InVita's robust portfolio serving complex medical environments," said Todd Collins, President and CEO of InVita. "Software that manages mission-critical operations, such as for human organ, tissue, eye and birth tissue donation and transplant is a natural fit for InVita. This investment furthers our mission to deliver the most innovative and comprehensive solutions for managing complex medical workflows. We are proud to be working with the leader in this space." 

The iTransplant? Platform supports nearly 75% of all deceased organ, tissue and eye donation in the United States and is used by more than 12,500 medical professionals across more than 100 organ, tissue, eye and birth tissue organizations around the world.

"We are truly excited by this investment from InVita," said John Piano, Founder, Chairman and CEO, Transplant Connect. "Through this investment, we'll be able to expand vital resources and capabilities and meaningfully grow our innovation ? allowing us to further connect the donation and transplant ecosystem and help save and heal more lives in the U.S. and around the world. Our combined resources will allow us to build on Transplant Connect's unparalleled 17+ years of success and take our offerings to the next level."

About InVita Healthcare Technologies 
InVita provides chain of custody software technologies for complex medical, forensic and community care environments. InVita's solutions optimize supply chains, sample tracking, and visibility across blood and plasma operations, the tissue and implant lifecycle, and environments spanning DNA and forensics. InVita's solutions support increased compliance and cost control, reduced risk, and improved patient and public safety outcomes.

About Transplant Connect
Founded in 2004 as a mission-driven medical software company, Transplant Connect is the world's leading provider of human biologics (organ, tissue, eye, placenta and other) donation and transplantation software. Included in the company's growing suite of solutions are iTransplant?, a secure cloud-based platform for clinical management, communications, analytics and logistics, and iReferral?, the first and only automated donor referral technology available to hospitals, medical examiners/coroners, organ procurement organizations, tissue banks and eye banks.

SOURCE Transplant Connect


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: